Goldman Sachs
CAI icon

Goldman Sachs’s Caris Life Sciences CAI Stock Holding History

Goldman Sachs’s Portfolio CAI Stock Details CAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17M Buy
951,942
+541,602
+132% +$9.69M ﹤0.01% 2806
2026
Q1 		$7.34M Buy
410,340
+60,198
+17% +$1.32M ﹤0.01% 3331
2025
Q4 		$9.45M Buy
350,142
+67,933
+24% +$1.91M ﹤0.01% 3147
2025
Q3 		$8.54M Buy
282,209
+99,956
+55% +$3.19M ﹤0.01% 3124
2025
Q2 		$4.87M Buy
+182,253
New +$4.91M ﹤0.01% 3448

Other funds holding CAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JHWEPV
J. H. Whitney Equity Partners VI New Canaan, Connecticut $201M AUM
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
SSP
Sixth Street Partners Dallas, Texas $579M AUM 2.46% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs's CAI Position: Q2 2026 in Review

Goldman Sachs increased its Caris Life Sciences (CAI) stake by 132% in Q2 2026, buying an estimated $9.69M and bringing the position to 951,942 shares worth $17M. The position accounts for ﹤0.01% of the portfolio, ranked #2806.

Goldman Sachs first reported a position in CAI in Q2 2025 and has held it in 5 quarters since. 247 funds tracked by Wall St. Rank hold CAI as of Q2 2026.

  • Goldman Sachs held 951,942 shares of Caris Life Sciences worth $17M as of Q2 2026.
  • Goldman Sachs bought 541,602 Caris Life Sciences shares in Q2 2026, an estimated $9.69M.
  • Caris Life Sciences made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #2806 holding.
  • Goldman Sachs first reported a position in Caris Life Sciences in Q2 2025 and has held it in 5 quarters since.
  • 247 funds tracked by Wall St. Rank held Caris Life Sciences as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.